Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
Lucas C, Vogels CBF, Yildirim I, Rothman JE, Lu P, Monteiro V, Gehlhausen JR, Campbell M, Silva J, Tabachnikova A, Peña-Hernandez MA, Muenker MC, Breban MI, Fauver JR, Mohanty S, Huang J, Shaw A, Ko A, Omer S, Grubaugh N, Iwasaki A. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature 2021, 600: 523-529. PMID: 34634791, PMCID: PMC9348899, DOI: 10.1038/s41586-021-04085-y.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 variantsMRNA vaccine-induced immunityT-cell activation markersSARS-CoV-2 antibodiesSecond vaccine doseVaccine-induced immunityCell activation markersT cell responsesHigh antibody titresSARS-CoV-2Vaccine boosterVaccine doseActivation markersVaccine dosesHumoral immunityAntibody titresMRNA vaccinesVitro stimulationNeutralization capacityNeutralization responseCell responsesE484KNucleocapsid peptideAntibody-binding sitesGreater reductionRisk of Sexually Transmitted Zika Virus in a Cohort of Economically Disadvantaged Urban Residents
Ticona J, Baig H, Nery N, Doss-Gollin S, Sacramento GA, Adhikarla H, Muenker MC, Wunder EA, Nascimento EJM, Marques ETA, Reis MG, Ko AI, Costa F. Risk of Sexually Transmitted Zika Virus in a Cohort of Economically Disadvantaged Urban Residents. The Journal Of Infectious Diseases 2021, 224: 860-864. PMID: 33395487, PMCID: PMC8522079, DOI: 10.1093/infdis/jiab001.Peer-Reviewed Original Research